The article discusses the surge in measles cases in the U.S., reaching a 35-year high, driven by declining vaccination rates.Researchers and biotech companies are now developing treatments like monoclonal antibodies and antivirals to address the growing public health crisis.Monoclonal antibodies, previously used for COVID-19, could provide short-term protection for vulnerable populations.However, challenges include manufacturing costs, clinical trial funding, and potential resistance from anti-vaccine groups.The article highlights the urgency of developing these treatments as measles could become endemic in the U.S.within 25 years.

Scientists at Vanderbilt University and others are working on potent antibodies, while antiviral drugs tested in animals show promise but require further human trials.

The piece emphasizes the need for continued research despite political and social challenges, as measles outbreaks pose significant risks to unvaccinated children and immunocompromised individuals.